Lexaria Bioscience and Cannadips CEO’s discuss key point of massive deal together

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California.

Bunka telling Proactive this is a massive deal for the company that will see products in roughly 5000 stores across the U.S. Mandel talks about why they went with Lexaria and how he feels this technology makes them a leader in the space.


Leave a Reply

Your email address will not be published. Required fields are marked *